Jack Bean Lectin Dosing for Stem Cell Abundance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are limited in increasing the abundance of hematopoietic stem cells in bone marrow and epidermal stem cells in the skin, which are essential for treating conditions such as stem cell depletion, immune suppression, leukemia, and skin disorders like lupus and psoriasis.
Innovation Solution
The use of Jack bean lectin or its pharmaceutically acceptable salt to increase the abundance of hematopoietic stem cells in bone marrow and epidermal stem cells in the skin through administration of a specific dose in an injectable formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods (GCSF, cytokines) are used to increase hematopoietic stem cells, then stem cell abundance increases, but treatment options remain limited and formulations for increasing intrinsic bone marrow stem cells are not available
Solution Approach 1:
The patent applies parameter changes by using Jack bean lectin at specific doses (1-250 mg, preferably 10-100 mg) to alter the biological response in bone marrow, achieving increased hematopoietic stem cell abundance through dose-dependent effects that differ from conventional cytokine-based approaches
Solution Approach 2:
Jack bean lectin serves as an intermediary substance that mediates the increase in hematopoietic stem cell abundance in bone marrow, providing a novel mechanism of action distinct from direct cytokine stimulation and expanding therapeutic options for stem cell depletion conditions
2Quantity of substance
If no specific formulation is used, then treatment of skin disorders (lupus, psoriasis, decubitus ulcers) is limited, but formulations for increasing epidermal stem cells in skin do not exist
Solution Approach 1:
The patent segments the therapeutic application into two distinct formulations: one for increasing hematopoietic stem cells in bone marrow (10-100 mg dose) and another for increasing epidermal stem cells in skin (1-10 mg dose), allowing targeted treatment of different tissue types with optimized dosing regimens
Solution Approach 2:
The patent applies parameter changes by establishing specific dose ranges for different tissue targets: 1-250 mg (preferably 10-100 mg) for bone marrow hematopoietic stem cells and 1-10 mg for skin epidermal stem cells, creating manufacturable formulations with defined dosing parameters
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively increases the abundance of hematopoietic stem cells in bone marrow and skin stem cells, providing a treatment for conditions related to stem cell deficiency and aplasia, as demonstrated by significant percentage increases in treated mice.
Implementation Method 1
Lectins are carbohydrate-binding proteins, and their interaction with any cell is dependent on the particular types of carbohydrate moieties present on the cell surface
Data Source
AI summary
A method of treatment of disease condition resulting from deficiency of hematopoietic stem and progenitor cells and/or epidermal stem cells in skin comprising: administering to the subject suffering from said disease conditions, an effective amount of Jack bean lectin or a pharmaceutically acceptable salt thereof for increasing the abundance of hematopoietic stem cells and progenitor cells in bone marrow and/or epidermal stem cells in skin in vivo. Method of treating said conditions in a subject involves administering a single injection of lectin in a dose range of 0.5-2.0 mg/kg body weight to mouse leading to 2.815 to 3.55 fold increase in the abundance of epidermal stem cells in skin and a dose range of 8.0-10.0 mg/Kg body weight to a mouse leading to 2.36 to 6.67-fold increase in the abundance of hematopoietic stem and progenitor cells in bone marrow.